DB
NKTR icon

Danske Bank’s Nektar Therapeutics NKTR Stock Holding History

Danske Bank’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$140 Hold
2
– – ﹤0.01% 1025
2026
Q1 		$144 Hold
2
– – ﹤0.01% 1034
2025
Q4 		$85 Hold
2
– – ﹤0.01% 1441
2025
Q3 		$114 Hold
2
– – ﹤0.01% 1389
2025
Q2 		$52 Buy
+2
New +$22 ﹤0.01% 1441

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Danske Bank's NKTR Position: Q2 2026 in Review

Danske Bank held its Nektar Therapeutics (NKTR) position steady in Q2 2026 at 2 shares worth $140. The position accounts for ﹤0.01% of the portfolio, ranked #1025.

Danske Bank first reported a position in NKTR in Q2 2025 and has held it in 5 quarters since. The position peaked at $144 in Q1 2026. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Danske Bank held 2 shares of Nektar Therapeutics worth $140 as of Q2 2026.
  • Danske Bank left its Nektar Therapeutics share count unchanged in Q2 2026.
  • Nektar Therapeutics made up ﹤0.01% of Danske Bank's portfolio in Q2 2026, its #1025 holding.
  • Danske Bank first reported a position in Nektar Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Danske Bank's Nektar Therapeutics position peaked at $144 in Q1 2026.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.